Whether the primary endpoint will survive FDA scrutiny from CMC comparability

Situation

The desk packet is CMC comparability package for a site change after a payer demanding RWE the protocol cannot generate. RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences FDA Response and Labeling file.

Decision

RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a payer demanding RWE the protocol cannot generate.

Hypotheses to test

• RWE evidence-strategy director can defend Proceed under protocol from CMC comparability package for a site change after a payer demanding RWE the protocol cannot generate in a Pharma & Life Sciences challenge.
• RWE evidence-strategy director cannot defend Proceed under protocol from CMC comparability package for a site change; Pause the pathway is what the extract actually supports after a payer demanding RWE the protocol cannot generate.
• A payer demanding RWE the protocol cannot generate never reached the population in CMC comparability package for a site change — reopen intake, do not close the primary endpoint will.
• Two facts in CMC comparability package for a site change after a payer demanding RWE the protocol cannot generate conflict for RWE evidence-strategy director; hold this FDA Response and Labeling file.

Analysis required

• Check whether CMC comparability package for a site change supports the labeled claim RWE evidence-strategy director would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a payer demanding RWE the protocol cannot generate.
• For this Pharma & Life Sciences FDA Response and Labeling file, read CMC comparability package for a site change against a payer demanding RWE the protocol cannot generate and write the one fact that would move the primary endpoint will for RWE evidence-strategy director.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (CMC comparability package for a site change after a payer demanding RWE the protocol cannot generate). The follow-on FDA Response and Labeling action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.